Translator Disclaimer
10 December 2020 Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome
Andrea M. Patterson, Tong Wu, Hui Lin Chua, Carol H. Sampson, Alexa Fisher, Pratibha Singh, Theresa A. Guise, Hailin Feng, Jessica Muldoon, Laura Wright, P. Artur Plett, Louis M. Pelus, Christie M. Orschell
Author Affiliations +
Abstract

Identification of medical countermeasures (MCM) to mitigate radiation damage and/or protect first responders is a compelling unmet medical need. The prostaglandin E2 (PGE2) analog, 16,16 dimethyl-PGE2 (dmPGE2), has shown efficacy as a radioprotectant and radiomitigator that can enhance hematopoiesis and ameliorate intestinal mucosal cell damage. In this study, we optimized the time of administration of dmPGE2 for protection and mitigation against mortality from the hematopoietic acute radiation syndrome (H-ARS) in young adult mice, evaluated its activity in pediatric and geriatric populations, and investigated potential mechanisms of action. Windows of 30-day survival efficacy for single administration of dmPGE2 were defined as within 3 h prior to and 6–30 h after total-body γ irradiation (TBI). Radioprotective and radio-mitigating efficacy was also observed in 2-year-old geriatric mice and 6-week-old pediatric mice. PGE2 receptor agonist studies suggest that signaling through EP4 is primarily responsible for the radioprotective effects. DmPGE2 administration prior to TBI attenuated the drop in red blood cells and platelets, accelerated recovery of all peripheral blood cell types, and resulted in higher hematopoietic and mesenchymal stem cells in survivor bone marrow. Multiplex analysis of bone marrow cytokines together with RNA sequencing of hematopoietic stem cells indicated a pro-hematopoiesis cytokine milieu induced by dmPGE2, with IL-6 and G-CSF strongly implicated in dmPGE2-mediated radioprotective activity. In summary, we have identified windows of administration for significant radio-mitigation and radioprotection by dmPGE2 in H-ARS, demonstrated survival efficacy in special populations, and gained insight into radioprotective mechanisms, information useful towards development of dmPGE2 as a MCM for first responders, military personnel, and civilians facing radiation threats.

©2021 by Radiation Research Society. All rights of reproduction in any form reserved.
Andrea M. Patterson, Tong Wu, Hui Lin Chua, Carol H. Sampson, Alexa Fisher, Pratibha Singh, Theresa A. Guise, Hailin Feng, Jessica Muldoon, Laura Wright, P. Artur Plett, Louis M. Pelus, and Christie M. Orschell "Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome," Radiation Research 195(2), 115-127, (10 December 2020). https://doi.org/10.1667/RADE-20-00181.1
Received: 24 July 2020; Accepted: 4 November 2020; Published: 10 December 2020
JOURNAL ARTICLE
13 PAGES


Share
SHARE
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top